Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more

Location: 855 Oak Grove Avenue, Menlo Park, CA, 94025, United States | Website: https://orukatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

576.7M

52 Wk Range

$5.49 - $31.13

Previous Close

$16.15

Open

$16.15

Volume

87,255

Day Range

$15.22 - $16.15

Enterprise Value

253.6M

Cash

328.4M

Avg Qtr Burn

-23.98M

Insider Ownership

3.82%

Institutional Own.

93.23%

Qtr Updated

06/30/25